the aid library

LIST OPTIONS

Filter

7959

Sort by:

Direction:

Download (336)

View PDF (554)

HIV, HCV, TB and harm reduction in prisons

G. Sander Harm Reduction International; European Union (2016) C1

Human Rights, Minimum Standards and Monitoring at the European and International Levels

Download (105)

View PDF (108)

A Roadmap to combat postpartum haemorrhage between 2023 and 2030

World Health Organization WHO (2023) C_WHO

WHO today released its first roadmap to tackle postpartum haemorrhage (PPH) – defined as excessive bleeding after childbirth - which affects millions of women annually and is the world’s leading cause of maternal deaths. Despite being preventable and treatable, PPH results in around 70 000 de... more

Download (121)

View PDF (218)

World Drug Report 2019 Booklet 5 Drugs and the environment

United Nations Office on Drug and Crime UNODC (2022) C2

The booklet starts with a general overview of how illicit drugs and the environment are linked within the bigger picture of the Sustainable Development Goals, climate change and environmental sustainability. It highlights direct and indirect linkages and gives examples of the significant local and i... more

Download (57)

View PDF (112)

Communities at the Centre

UNAIDS (2019) C2

Defending Rights Breaking Barriers Reaching People with HIV Services Global Aids Update 2019

Download (96)

View PDF (229)

The Paris Principles: Principles and Guidelines on Children associated with Armed Forces and Armed Groups

United Nations Children's Fund (UNICEF) (2007) C1

The recruitment and use of children violates their rights and causes them physical, developmental, emotional, mental, and spiritual harm. The impact on their mental and physical well-being breaches the most fundamental human rights and represents a grave threat to durable peace and sustainable deve... more

Download (176)

View PDF (247)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (111)

View PDF (192)

Laboratory testing for the monkeypox virus
recommended

World Health Organization (WHO) (2022) C_WHO

Any individual that meets the suspected case definition of monkeypox should be offered testing in appropriately equipped laboratories by staff trained in the relevant technical and safety procedures. Confirmation of monkeypox virus infection is based on nucleic acid amplification testing (NAAT), usi... more

Download (167)

View PDF (277)

UNFPA Myanmar Annual Report 2017

United Nations Population Fund (UNFPA) (2018) C1

Ensuring reproductive rights for all

Download (59)

View PDF (132)

Air pollution and child health: prescribing clean air: summary

World Health Organisation (WHO) (2018) C_WHO

This report summarizes the latest scientific knowledge on the links between exposure to air pollution and adverse health effects in children. It is intended to inform and motivate individual and collective action by health care professionals to prevent damage to children’s health from exposure to ... more

Download (46)

View PDF (74)

Persons with disabilities as experts-by experience: using personal narratives to affect community attitudes in Kilifi, Kenya

Joseph K. Gona, Newton C.R., Hartley, Sally, et al. (2018) C1

International Health and Human Rights (2018) 18:18 Disability awareness, Community, Attitudes, Experts-by-experience

Download (516)

View PDF (1365)

Assessment of prison life of persons with disability in Ghana

Joslin Dogbe, Ellis Owusu-Dabo, Anthony Edusei et al. (2016) CC

BioMed Central; BMC International Health and Human Rights (2016) 16:20; DOI 10.1186/s12914-016-0094-y

Download (1265)

View PDF (1035)

Enhancing Mental Health and Psychosocial Support Capacity in Low Resource Settings

Wendy Ager, Yvonne Sliep and Reem Ibrahim Ahmed, et al. War Trauma Foundation, Ahfad University for Women; et al. (2015) C1

From Individual to Collective healing: A trainer’s manual

Download (152)

View PDF (180)

Caught in Crossfire - Children and education in regions affected by civil strife

Save the Children (2013) C2

This study primarily aims to understand how children living in areas of civil strife are denied their basic rights, especially the right to education and protection. For this study, eight districts affected by civil strife across the three states (Chhattisgarh: Dantewada, Bijapur, Bastar and Narayan... more